form as the proposed target. Of 17 compounds, only the DNA gyrase inhibitor coumermycin A1 was active. This inhibition was observed for two HIV isolates in both MT-2 cells and peripheral blood leucocytes, and could not be attributed to cytotoxicity. Coumermycin A1 did not inhibit HIV reverse transcriptase activity in an in vitro assay at concentrations that inhibited HIV replication in infected cells; its precise mechanism of action remains to be elucidated.
Introduction
The emergence of the acquired immunodeficiency syndrome (AIDS) has resulted in major efforts to identify compounds active against the aetiological agent, the human immunodeficiency virus (HIV). The nucleoside analogue zidovudine (azidothymidine, AlT) is at present the only drug in widespread use for the treatment of AIDS; however, its limited efficacy and toxicity (Yarchoan et al., 1989) and the emergence of AZT-resistant isolates (Larder et al., 1989) have resulted in a search for other active drugs. Although nucleoside analogues targeted at the reverse transcriptase (RT) are an obvious choice, drugs with activity directed at other sites may play an important role in the control or eradication of HIV infection. HIV is classified within the lentivirinae subfamily of the family Retroviridae. Following binding and internalization of HIV, viral genomic RNA is transcribed into a double-stranded DNA form through the action of a virion-associated RT. Before integration, HIV DNA appears to exist in three forms, linear duplex DNA with a complete long terminal repeat (LTR) at each end, and two closed circular DNAforms, one with a single copy of the LTR and the other with two copies joined in tandem (Haseltine, 1989) . It is unclear which DNAform is the integration precursor. While the Closed circular DNA form containing two copies of the LTR appears to be favoured in the avian reticuloendotheliosis virus system (Panganiban and Temin, 1984) , recent studies on murine leukaemia viruses (Brown et al., 1987; Fugiwara and Mizuuchi, 1988; Ellis and Bernstein, 1989; Lobel et al., 1989) suggest that the linear form may be preferred.
In the lambda bacteriophage model, the covalently closed or supercoiled (SC) DNA form has been shown to be the most efficient substrate for integration into the host chromosome (Gellert et al., 1976b; Vosberg, 1985; Richet et al., 1986) , and since viral SG DNA is also present in HIV-infected GEM and MT-2 T-Iymphocyte lines (Stevenson et al., 1988; G. Tachedjian, unpublished data) , we asked whether HIV replication could be inhibited at the level of SG DNA processing, thus preventing HIV integration and ultimately HIV replication.
The topological state of DNA is controlled by topoisomerases through a nicking and resealing mechanism (Vosberg, 1985) involving transient single (type I) or double-stranded (type II) nicks. Apart from their involvement in supercoiling, topoisomerases are also important in other DNA-dependent processes, including DNA rep-Ilcation, transcription and recombination (Vosberg, 1985) . DNA can be negatively supercoiled by two different mechanisms. In eukaryotic cells, this is achieved by cellular DNA wrapping around histone proteins to form nucleosomes. Topoisomerases I and II are implicated in this process (Glikin et al., 1984; Ryoji and Worcel, 1984; Vosberg, 1985) , the former to relax positive superhelical tension within the internucleosomal regions, and the latter to wrap the DNA around histone proteins (Vosberg, 1985) . In prokaryotes, supercoiled DNA is generated by DNA gyrase (also a topoisomerase type II), which differs from the eukaryotic equivalent in that it actively introduces negative supercoils in the absence of any histone-like proteins (Gellert et al., 1976a) . If the SG form of HIV DNA is Table 1 . Toxicity and anti-HIV activity of topoisomerase inhibitors and DNA-active compounds in MT-2 cells.
The MTD and anti-Hlv activity of compounds were determined in mycoplasma-free MT-2 cells as described in the Materials and Experimental procedures. (+) represents an active compound; (-) indicates an inactive compound. Drugs were considered active against HIV if significant inhibition of viral CPE (>95%) was observed at the MTD. Inhibitors were prepared as 10mgml-1 stocks, with the exception of neocarzinostatin which was available as a 1000 U mr ' solution in 0.015M NaAcetate. Nalidixic acid, oxolinic acid, norfloxacin, ciprofloxacin and acrosoxacin were solubilized in sterile 0.1 M KOH. Doxorubicin was dissolved in sterile water, gramicidins D and S in ethanol, ellipticine in 0.01 MHCI and the remaining compounds in DMSO. coumermycin A1 was determined by counting viable ce11s at the conclusion of the experiment. After 6 days in culture, a 10 J-Lg mr' concentration of coumermycin A1 was clearly toxic, producing a 26% decrease in cell numbers and a greater than 80% inhibition in cellular protein, RNA and DNA synthesis (Table 2) . At 5 J-Lg rnr' no significant inhibition of viable cell counts and DNA synthesis was observed, although a low level of inhibition in both protein and RNA synthesis was apparent (Table 2) . Coumermycin A1 at 2.5 J-Lg mr' showed no effect on any of the toxicity indicators examined, while this concentration reproducibly inhibited HIV replication in these cells (Figs 1,2 and 3). At 6 days post-infection (p.i.) CPE was maximal in virus-infected cells cultured in the absence of drug, while the ddC control showed complete inhibition of HIV replication ( Fig. 1 ). In the presence of coumermycin A1, both isolates were inhibited in a dose-dependent manner as measured by CPE ( Fig. 1 ), particle-associated RT activity ( Fig. 1 ) and p24 core antigen (Fig. 2) . The titre of extracellular virus in the drug-treated culture supernates also 
Results

Anti-HIV activity of coumermycin A 1 in MT-2 cells
The activity of coumermycin A1 was investigated further to determine whether different stains of HIV exhibited similar susceptibility to the drug. In experiments in MT-2 cells using isolates nos 237288 and 228200, the toxicity of histone-associated then cellular topoisomerases might be involved in its generation. However, if HIV SC DNA is naked, a DNA gyrase-like activity could be encoded by the virion. Alternatively, the supercoiling process may involve previously unrecognized cellular and/or viral mechanisms. Inhibitors of eukaryotic topoisornerase I and II are well recognized. They include camptothecin for topolsornerase I (Garq et al., 1987) and amsacrine, doxorubicin, ellipticine and the epipodophyllotoxins etoposide and teniposide for topoisomerase II (Wang, 1987; Epstein, 1988) .These compounds are potent anti-neoplastic drugs (Bodley and Liu, 1988; Epstein, 1988) which interfere with the breaking and resealing reaction of topoisomerases by stabilizing a cleavable complex.
Prokaryotic DNA gyrase inhibitors have also been reported, and include nalidixic acid, oxolinic acid, novobiocin and coumermycin A1 (Vosberg, 1985) . Compounds that cleave or intercalate differentially to non-protein-associated SC DNA include neocarzinostatin (Grimwade and Beerman, 1986 ) and gramicidins (Bohg and Ristow, 1986) .
We have examined the in vitro activity against HIV of several DNA gyrase and topoisomerase inhibitors and DNA binding and/or cleaving compounds in an effort to identify potentially useful compounds, and to indirectly provide further evidence as to the role of SC DNA in the overall replication of HIV. Of the compounds tested, the DNA gyrase inhibitor coumermycin A1 was the only active drug.
Anti-HIV activity of topoisomerase inhibitors and DNA binding/cleaving compounds
We initially screened a series of topoisomerase inhibitors and DNA interacting compounds for their ability to inhibit HIV replication in MT-2 cells (Table 1) . Of the DNA gyrase inhibitors, only coumermycin A1 significantly inhibited the cytopathic effect (CPE) at the highest non-toxic concentrations tested.
As expected, the inhibitors specific for the eukaryotic topoisomerases were significantly more toxic in MT-2 cells compared to the prokaryotic-specific DNA gyrase inhibitors (Table 1) . While the positive drug control, ddC, completely inhibited development of CPE at 1.0 J-Lg rnr', none of these inhibitors, nor the DNA interacting drugs, were active.
showed a similar trend (Fig. 3 ). The antiviral index (AI), defined as the maximum tolerated dose (MTD)of the drug divided by the dose at which it caused 50% inhibition of RT activity, was 5 and 8 for isolates nos 237288 and 228200, respectively. 
Discussion
In vitro inhibition of RT activity An in vitro assay to determine if coumermycin A1 was able to inhibit HIV RT was performed using ddC and ddCTP as negative and positive controls, respectively. When a standard amount of RT (250000c.p.m.) was incubated with coumermycin A1, no inhibition of enzyme activity was observed at doses ranging from 0.005 to 5 J-Lg mr'.In the same assay, ddCTP displayed a dose-dependent inhibition, and ddC was inactive ( Fig. 5 ). Coumermycin A1 at 50 fL9 rnl" consistently inhibited RT activity by 40%. However, this was an artificial inhibitory result since it was observed that a component(s) in the reaction mix precipitated out at this concentration.
In this study we investigated the possibility that inhibitors of prokaryotic DNA gyrase, eukaryotic topoisomerase types I and II, and compounds that directly interact with DNA, might inhibit HIV replication. On the basis of the types of drugs tested, and their mechanism of action, we hoped to gain insights into the role of topoisomerases in the replication strategy of HIV, particularly the nature of the SC DNA and the function of this species in the integration process.
Of the 17 drugs tested, the only one to inhibit HIV replication in MT-2 cells was coumermycin A1. Coumermycin A1, an inhibitor of DNA gyrase, is an antibiotic produced by Streptomyces spp. (Berger et al., 1966) . It also has activity against murine retrovirus replication in vitro (Varnier et sl., 1984) , with drug-resistant isolates Anti-HIVaetivity of coumermycin A 1 in PSL The anti-H IV activity of coumermycin A1 was also investigated in peripheral blood leucocytes (PBL) infected with isolate no. 237288 following a 2 h preincubation at 37°C with the drug. This treatment produces a dose-dependent inhibition of replication, as measured at Day 6 ( Fig. 4) , with an AI of 5, the same as for isolate no. 237288 in MT-2 cells. By way of comparison the AI for ddC in PBL was 35. Table 2 . Cytotoxicity of coumermycin A1 and its effects on the metabolic activities of MT-2 cells. properties of coumermycin A1 enable it to bind to the active site of an HIV-encoded gyrase-like enzyme in preference to other inhibitors. Further studies will be required to determine whether HIV encodes a coumermycin A1-sensistive topoisomerase. Interestingly, a relaxing topoisomerase activity has been identified in the alphabeta isoenzyme of avian sarcoma virus RNA-dependent polymerase (Hizi et al., 1982) ; however, no supercoiling activity of this enzyme was reported.
Coumermycin A1 has been reported to inhibit the replication of Influenza A (Portincasa et al., 1984) and herpes simplex virus (HSV) (Palu et al., 1986) . The replication strategies ofthese two viruses, and that of HIV, are widely divergent. Influenza A is an RNA virus whose replication is facilitated through a virion-associated RNAdependent RNA polymerase. Therefore, DNA in any topological form is not an expected intermediate in the replication cycle. HSV possesses a linear double-stranded DNA genome, and while DNA intermediates are detectable at various stages of the replication cycle there is no evidence for the presence of a SC topological form in a productive infection (Palu et al., 1986) . In the case of Influenza A, drug concentrations from 3 to 60 fL9 rnr' produced a reduction in haemagglutinin titre, while a concentration of 1.0 fL9 rnr" produced a 50% inhibition of HSV yield. In both cases, the apparent inhibition of virus replication occurred in non-proliferating cells at concentrations of drug which were clearly toxic (by virtue of their inhibition of host cell protein, RNA and DNA synthesis). In support of this, coumermycin A1 has also been shown to bind non-specifically to DNA, RNA and protein (Masotti et al., 1984; Palu et al., 1986 ). In our system, metabolic labelling in uninfected cells treated with coumermycin A1 being described (Varnier et al., 1985) . In the light of these results, we investigated the activity of coumermycin A1 against solubilized RT in an in vitro assay, but could find no inhibitory activity at biologically relevant concentrations. Thus, RT does not appear to be a target for inhibition by coumermycin A1. The ability of a DNA gyrase inhibitor such as coumermycin A1 to affect HIVreplication raisesthe possibility that an enzyme with gyrase-like activity is present within infected cells. However, eukaryotic cellular topoisomerases do not possess gyrase activity, suggesting that the enzyme responsible for introducing superhelical turns to produce HIV SC DNA may be virion-encoded. It could be argued that if a DNA gyrase-like activity was responsible for introducing supercoils into HIVDNA,then it would be expected that other gyrase inhibitors, such as novobiocin and naladixic acid, should also exhibit HIV inhibitory activity. However, this is not the case in our system and to explain our data the postulated HIV gyrase-like activity must be sensitive to coumermycin A1 alone. It is not difficult to envisage a situation where the unique structural 20 studies with the spleen necrosis virus (Panganiban and Temin, 1984) reveal that the circular form is the precursor. Studies on HIV itself, or other closely related lentiviruses, are necessary to determine the situation in the HIVsystem.
Neocarzinostatin, the gramicidins and tyrothrycin were all inactive as inhibitors of HIV replication. Neocarzinostatin is able to bind and cleave DNA directly (Grimwade and Beerman, 1986) , whereas the gramicidins and tyrocidin intercalate (Bohg and Ristow, 1986) . The rationale behind screening neoccirzinostatin was that it could selectively bind to naked HIV SC DNA as distinct from histoneassociated cellular chromatin, thus preferentially cleaving it. A similar rationale was adopted in testing the gramicidins and tyrothrycin, with the inference that the SC HIV DNA would not be cleaved but converted to a relaxed form, this not being the preferred substrate for integration.
There are reports of inhibition of virus replication by topoisomerase inhibitors (Kreuzer, 1989) . Amsacrine and teniposide can inhibit the replication of human cytomegalovirus in vitro (Benson and Huang, 1988) . Novobiocin and nalidixic acid, active against eukaryotic topoisomerase II as well as prokaryotic DNA gyrase, can inhibit SV40 DNA and RNA synthesis (Yang et el., 1987; Waldeck et al., 1988) . Snapka (1986) has reported the inhibition of decatenation of daughter chromosomes and the breakage in replication forms in Cairns structures in SV40 replication by topoisomerase II and I inhibitors, respectively. Civitico showed the drug to significantly inhibit cellular protein, RNA and DNA synthesis, but not at concentrations at which a specific antiviral effect could be demonstrated. It should also be noted that during HIV inhibition assays carried out in the presence of coumermycin A1, the number of MT-2 cells increased from an input of 1 million to more than 6 million at antiviral concentrations over a 6-day period. This, together with the presence of a potential target for the drug (that is, SC DNA), supports a virus-specific role for the inhibitory activity of coumermycin A1. By analogy with the prokaryotic DNA gyrase, the eukaryotic topoisomerase I and II enzymes have been implicated in the assembly of cellular chromatin and hence supercoiling of DNA (Glikin et al., 1984; Ryoji and Worcel, 1984) . If HIV SC DNA is histone associated, implicating eukaryotic topoisomerase I and 1\ activity for its synthesis, it would be reasonable to suggest that inhibition of these enzymes would affect HIV SC DNA. The lack of activity of the eukaryotic topoisomerase inhibitors we tested can be explained in several ways. (i)HIV SC DNA is histone-associated, resulting in a lack of selectivity for the viral species due to its similarity in structure to cellular chromatin. (ii)HIV SC DNA is not histone-associated but naked, thus implicating a virion-encoded gyrase-Iike activity responsible for its generation. (iii) Topoisomerases are necessary for the generation of SC DNA, but SC DNA may not be important in the replication of HIV, in particular as a direct integration precursor.
Several studies suggest that the linear DNA form of murine retroviruses is the direct integration precursor (Brown et al., 1987; Fugiwara and Mizuuchi, 1988; Ellis and Bernstin, 1989; Lobel et al., 1989) . However, similar While it is assumed that integrated DNA is the transcriptional template for HIV, the possibility exists that unintegrated viral cDNA containing two copies of the LTR can be used for RNA synthesis (Haseltine, 1989) . It has been shown for the lentivirus visna, that the predominant DNA species in the infected cell is the linear duplex from (Harris et a/., 1981) which subsequently serves as the template for transcription and virus production (Harris et a/., 1984) . Similar findings have been reported for spleen necrosis virus, an avian type C retrovirus, where a replication-competent but integration-defective virus was described (Panganiban and Temin, 1983). The situation for HIV is yetto be resolved.
In conclusion, we have shown that while coumermycin A 1 has in vitro activity against HIV, it does not inhibit RT at biologically relevant concentrations. Its precise mechanism of action at the molecular level remains to be established, particularly with regard to events occurring at the levels of SC DNA production and integration. The topoisomerase I and II inhibitors and DNA interacting compounds we tested appear not to have a role as potential AIDS therapeutics. Our results suggest that if the HIV SC form is the integration precursor, then it may be supercoiled by a virion-encoded enzyme having sensitivity to the DNA-gyrase inhibitor coumermycin A 1. Our finding of activity for coumermycin A 1 will hopefully provide further insights into the replication strategy of HIV, and possible future therapeutic targets.
Materials and Experimental procedures
Cells MT-2 cells (Harada et a/., 1985) were cultured in RPMI medium containing RPMI-1640 (Gibco, Grand Island, Ny), 10% (v/v) heat-inactivated fetal calf serum, 29.2 fL9 rnr' glutamine, 100U ml-1 penicillin, 100 fL9 ml-1 streptomycin and 0.1% NaHCO s . Human PBL were obtained from HIV seronegative donors and prepared as described previously (Neate et a/., 1987) . Mononuclear cells were incubated for 3 days in RPMI medium containing 10 fL9 mr ' of phytohaemaglutinin (PHA). For use in antiviral drug assays they were transferred to IL-2 medium. [RPMI medium supplemented with 20 Umr ' recombinant interleukin-2 (Boehringer Mannheim, Mannheirn, FRG), 4 fL9 mr ' hydrocortisone, 20o.1Uml-1 anti-alpha interferon (ICN Immunobiologicals, Lisle, IL) and 2 fL9 rnr' polybrene].
Viruses
HIV-1 strain nos 237288 and 228200 were isolated from peripheral blood mononuclear cells of AIDS patients undergoing treatment at Fairfield Hospital. The isolates were chosen for their rapid growth to high titre and production of characteristic cytopathic effect (CPE) in both MT-2 and PBL. Stocks of 237288 and 228200 were passaged and titred in the cell type used in the antiviral assays. Drugs The following compounds were tested for antiviral activity: dideoxycytidine (ddC; Sigma D -5782, St Louis, MO), nalidixic acid quinoline-7 -carboxylic acid; Sigma 0-0877),coumermycinA 1(SigmaC-9270),novobiocin (N(7 -((3-0~(Aminocarbonyl)-6-deoxy-5-C-methyl-4-0-methyl-f3-L -Iyxopyranosyl)oxy)-4 -hydroxy -8 -methyl -2 -oxo -2H -1benzopyran -3 -yl) -4 -hydroxy -3 -(3 -methyl -2 -butenyl) benzamide; Sigma N -1628), camptothecin (4-ethyl-4 -hydroxy-1H -pyrano -(3',4':6,7)indolizino (1 ,2-b)quinoline-3,14(4H,12H)dione; SigmaC -9911), ellipticine (5,11 -Dimethyl-6H -pyrido)4,3b)carbazole;SigmaE-3380), amsacrine(N-(4-(9 -Acridinylamino) -3 -methoxyphenyl)methanesulphonamide;Parke Davis,Caringbah, NSW, Australia), etoposide (9 -((4,6 -0 -ethylidene -f3 -Dglucopyranosyl)oxy) -5,8,8a,9 -tetrahydro -5 -(4 -hydroxy -3,5dimethoxyphenyl) furo(3',4':6,7)naphtho(2,3 -d) -1,3 -dioxol -6(5aH)-one;4'-demethylepipodophyllotoxin 9-(4,6-0 -ethylidene -f3 -D -glucopyranoside, VP -16; Bristol -Myers, Clayton, Vic, Australia),teniposide (5,8,8a,9-tetrahydro -5 -(4 -hydroxy -3 ,5dimethoxyphenyl) -9 -((4,6 -0 -(2 -thienylmethylene) -f3 -Dglucopyranosyl)oxy)furo(3',4':6,7)lnaptho(2,3 -d) -1,3 -dioxol-6(5aH) -one;4' -demethylepipodophyllotoxin 9 -(4,6 -0 -2thenylidene -f3 -D -glucopyranoside, VM -26; Bristol -Myers), doxorubicin (10 -((3 -amino -2,3,6 -trideoxy -IT -Llyxohexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8 -(hydroxyacetyl)-1 -methoxy -5, 12-napththacenedione; Sigma D-1515), gramicidin D(SigmaG5002),gramicidin S Hydrochloride (C6oH29N1201O; SigmaG-5127),neocarzinostatin(Bristol-Myers), tyrothricin (10-20% gramicidin and 40-60% tyrocidine; Serva, Heidelberg, FRG), norfloxacin (1 -ethyl-6-fluoro -1,4 -dihydro -4oxo -7 -1 -piperazinly)-3-quinolinecarboxylic acid; Merck Sharp& Dohme, Darmstadt, FRG), ciprofloxacin (Bayer Botany, NSW, Australia), acrosoxacin (Sterling Pharmaceuticals, Ermington, NSW,Austrlia)and dideoxycytidinetriphosphate (ddCTP;SigmaD -7159).Drugs were prepared fresh for toxicity and antiviraltesting as indicated.
Toxicity studies
The toxicity of each drug was determined initially in MT-2 cells by incubating serial dilutions of drug with uninfected cells for 7 days at 3ynC. An equal volume of medium containing fresh drug was added at Day 3 or 4. Concentrations producing an observable decrease in cell numbers, as seen by light microscopy, were considered toxic. The maximum tolerated dose (MTD) was defined as the highest concentration of drug not toxic to the cells. A more extensive analysis of the toxicity of coumermycin A1 in MT-2 cells and PBL was performed in parallel with the antiviral testing by counting viable cells (as determined by trypan blue exclusion) at the conclusion of the assay. The effect on cellular protein, RNA and DNA synthesis was determined in uninfected MT-2 cells in the presence of 0, 2.5, 5, and 10fLgml-1-of coumermycin A1. MT-2 cells were seeded at 1 x 10 6 per flask in the presence of drug. A half medium change was performed as described for the antiviral drug assays. At Day 6 post-seeding, cells were labelled for 3h with either PH] leucine (8fLCi ml-1), [SH] thymidine (5/-l-Ci mr') or FH] uridine (5/-l-Ci ml-1 ) , washed with ice-cold isotonic saline, lysed with 2% sodium dodecyl sulphate and precipitated with trichloroacetic acid to determine the incorporated radioactivity.
Antiviral drug assays
The activity of each drug was initially tested in a screening assay based on inhibition of virus-specific CPEin MT-2 cells (Birch et al., 1988) . Tenfold dilutions of the drugs were preincubated for 2 hat 3rC with 1 x 10 6 MT-2 cells in duplicate 25cm 2 flasks. HIV isolate no. 237288, at an inoculum of 250 TCID 5 0 , was added to the flasks, which were incubated at 3rC. At Day 3 or 4 (p.i.), half the volume of the culture supernate was aspirated and replenished with an equal volume of medium containing fresh drug at the appropriate concentration. CPE was read in drugtreated cultures when the CPE in an infected control, cultured in the absence of drug, was maximal. Drugs inhibiting development of CPE by more than 95% at the MTD were considered active. A positive control (dideoxycytidine at 1/-l-gml-1 ) and toxicity controls (1 x and 2 x the MTD for each drug) were included in all assays.
Coumermycin A1 was examined further in both 237288-and 228200-infected MT-2 cells and in 237288-infected PBL. The procedure was similar to that described above, except that at the conclusion of the assay supernates were clarified by low-speed centrifugation and assayed for virion-associated RT, p24 content and infectious virus. In assays performed in MT-2 cells, 1 x 10 6 cells per flask were infected with 250 and 500 TCID 5 0 of 237288 and 228200, respectively. In assays using PBL, 1.2 x 10 6 cells were infected with 50 TCID 5 0 of virus.
Measures of HIVexpression
Supernatant fluids were assayed for particle-associated RT activity using a microassay method as described previously (Neate et al., 1987) , while p24 core antigen was detected using an HIVAG-1 enzyme immunoassay kit (Abbott Laboratories, North Ryde, NSW, Australia) and quantified from a standard curve. Titres of extracellular infectious virus were determined using an infectivity assay, performed in quadruplicate in MT-2 cells over 7 days.
In vitro RT inhibition assay
The extent of inhibition of HIV RTwas determined using an in vitro assay with solubilized isolate no. 237288 as the source of RT. Polyethylene glycol-precipitated virus was disrupted in virus solubilization buffer containing 1% Triton X-100,1 mMphenylmethylsulphonyl fluoride, 1.6 M NaCI, 40% glycerol and 100 nMTris, pH 7.8. Serial 1O-fold dilutions of ddC, ddCTP and coumermycin A1 were prepared in sterile deionized water ranging from 1000 to 0.1/-l-g mr". Fifty microlitres of diluted drug were added to an equal volume of solubilized virus and 20 fLl of this mixture applied to 180 fLl of reaction mix containing 50mM Tris, pH 7.8, 0.1 U mr' poly (rA). p(d1)10 (Pharmacia, Uppsala, Sweden), 10 mM MgCI2 , 5mM dithiothreitol, 80/-l-gml-1 dATP and 50fLCi mr" of FH]TTP (40-60 Ci mmol-1; Amersham, Amersharn, Bucks, UK). The reaction was allowed to proceed for 2 h at 3rC, then stopped by the addition of 50 /-l-I of 50% trichloroacetic acid (TCA). TCA-insoluble counts were harvested onto glass-fibre filter (GFA) paper and counted in a Packard 300CD counter.
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